Standard Biotools Inc. LAB
Biotechnology: Laboratory Analytical Instruments · IPO 2011 · data as of November 13, 2026
Standard Biotools Inc. (LAB) is a industrial company listed in the US with a market value of about $279M. In the twelve months to September 30, 2026 it had revenue of $84M and net income of $133M, a net margin of 157.6%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is value (2/5); the weakest is track record (0/5).
Key numbers: a P/E of 2.1, 5-year revenue growth of -9% a year, a 5-year average ROIC of -154%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 82% below the current price.
About Standard Biotools
Standard Biotools is listed in the US and classified in biotechnology: laboratory analytical instruments, IPO year 2011. Revenue went from $116M in 2014 to $85M in 2025, a decline of about 2.8% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 387% over three years (dilution for shareholders). It spends 30% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $84M | $85M | $91M | $106M | $98M | $131M | $138M | $117M | $113M | $102M | $104M |
| Net income | $133M | -$75M | -$139M | -$75M | -$190M | -$59M | -$53M | -$65M | -$59M | -$61M | -$76M |
| Free cash flow | -$66M | -$83M | -$152M | -$46M | -$93M | -$57M | -$28M | -$38M | -$26M | -$26M | -$44M |
| EPS (diluted) | $0.34 | $-0.20 | $-0.52 | $-0.94 | $-2.43 | $-0.78 | $-0.74 | $-0.97 | $-1.49 | $-1.84 | $-2.62 |
| Net margin | 157.6% | -87.8% | -152.6% | -70.2% | -194.1% | -45.4% | -38.4% | -55.3% | -52.2% | -59.4% | -72.8% |
| ROIC | — | -14.7% | -20.0% | — | -540.4% | -41.3% | -27.8% | -31.5% | -64.2% | -179.0% | -130.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $1.35, 91% above the current price; targets range from $1.35 to $1.35; the consensus rating is “none”.
Frequently asked questions
What is Standard Biotools’s P/E ratio?
About 2.1, based on the last twelve months of diluted earnings per share.
Is Standard Biotools stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 82% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Standard Biotools pay a dividend?
Not currently.
Is Standard Biotools a good stock to buy?
We do not give buy or sell advice. Standard Biotools scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.